Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lorenzo Argante"'
Autor:
Lorenzo Argante, Victoria Abbing-Karahagopian, Kumaran Vadivelu, Rino Rappuoli, Duccio Medini
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background The four-component serogroup B meningococcal 4CMenB vaccine (Bexsero, GSK) has been routinely given to all infants in the United Kingdom at 2, 4 and 12 months of age since September 2015. After 3 years, Public Health England (PHE)
Externí odkaz:
https://doaj.org/article/4b15ce53676446c3ab0e88760506e9ce
Autor:
Lorenzo Argante, Barana, Benedetta, Cappelli, Eva, De Rui, Maria Elena, Galia, Liliana, Geurtsen, Jeroen, Guedes, Mariana, Mejia, Jorly, Palladino, Andrea, Pezzani, Maria Diletta, Piljic, Alen, Kingston, Rhys, Vella, Venanzio, Pouwels, Koen B., Schmidt, Johannes E., Abdelatif El-Abasiri, Radwa A., Reyna-Villasmil, Eduardo, Hassoun-Kheir, Nasreen, Harbarth, Stephan, Rodríguez-Baño, Jesús, Tacconelli, Evelina, Arieti, Fabiana, Gladstone, Beryl Primrose, de Kraker, Marlieke E.A., Naylor, Nichola R., Robotham, Julie V.
Publikováno v:
In Clinical Microbiology and Infection March 2024 30 Supplement 1:S26-S36
Autor:
Rino Rappuoli, Lorenzo Argante, Victoria Abbing-Karahagopian, Kumaran Vadivelu, Duccio Medini
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-10 (2021)
Background The four-component serogroup B meningococcal 4CMenB vaccine (Bexsero, GSK) has been routinely given to all infants in the United Kingdom at 2, 4 and 12 months of age since September 2015. After 3 years, Public Health England (PHE) reported
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b40f50f844357d3ed5a40cdf6d114b2a
https://doi.org/10.1186/s12879-021-06906-x
https://doi.org/10.1186/s12879-021-06906-x
Publikováno v:
American journal of epidemiology. 191(4)
Invasive meningococcal disease (IMD) has a low and unpredictable incidence, presenting challenges for real-world evaluations of meningococcal vaccines. Traditionally, meningococcal vaccine impact is evaluated by predicting counterfactuals from pre-im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1aeccfb78486141d25bd6ba4a4f5c1c
https://pubmed.ncbi.nlm.nih.gov/34753175
https://pubmed.ncbi.nlm.nih.gov/34753175
Autor:
E. Beck, Kumaran Vadivelu, Orjan Akerborg, Mohamed Neine, Stephanie Garcia, Kinga Meszaros, Johan Klint, Rafik Bekkat-Berkani, Jane Whelan, Lorenzo Argante, Cosmina Hogea, Victoria Abbing, Véronique Abitbol
Publikováno v:
Vaccine. 38(47)
Invasive meningococcal disease (IMD), an uncommon but severe disease, affects mainly infants, young children and adolescents. Meningococcal B (4CMenB) and ACWY (MenACWY) vaccines targeting IMD-causing serogroups B and A, C, W and Y, respectively are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4899f9d9c47bbae69dc8a3063219491b
https://pubmed.ncbi.nlm.nih.gov/32807531
https://pubmed.ncbi.nlm.nih.gov/32807531
Publikováno v:
BMC Medicine
Background Estimating the effectiveness of meningococcal vaccines with high accuracy and precision can be challenging due to the low incidence of the invasive disease, which ranges between 0.5 and 1 cases per 100,000 in Europe and North America. Vacc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0820183ed5546af9152430d40160b7f